Brian Slomovitz

14PUBLICATIONS
86CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer diagnosisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 10, 2026
Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

|Dec 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Brian M Slomovitz, S John Weroha, Wei Deng

|Dec 02, 2025
Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.

Vivek Podder, Robert L Coleman, Andrea R Hagemann

|May 16, 2025
Comprehensive management of vulvovaginal cancers.

Angélica Nogueira-Rodrigues, Maaike H M Oonk, Domenica Lorusso

|Apr 26, 2025
Examining the Association of Body Mass Index and Complications When Including Sentinel Lymph Node Biopsy in Minimally Invasive Surgery for Endometrial Intraepithelial Neoplasia.

Gabriel Levin, Pedro T Ramirez, Jason D Wright

|Oct 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Brian M Slomovitz, David Cibula, Weiguo Lv

Pageof 3

Frequent Collaborators

5 joint publications

Bradley J Monk

4 joint publications

Robert L Coleman

3 joint publications

Thomas J Herzog

3 joint publications

Bhavana Pothuri